Advertisement

Opioid responsiveness of nociceptive versus mixed pain in clinical cancer patients

Published:November 12, 2018DOI:https://doi.org/10.1016/j.ejca.2018.09.036

      Highlights

      • Cancer pain driven by neuropathic mechanisms is believed to be opioid resistant.
      • We find similar opioid requirements in nociceptive and mixed cancer pain patients.
      • Mixed cancer pain may be considered a type of nociceptive pain.

      Abstract

      Objective

      To investigate whether clinical cancer patients with mixed nociceptive–neuropathic pain are less responsive to opioids than patients with nociceptive pain.

      Background

      Pain is common in advanced cancer patients. Pain driven by neuropathic mechanisms is considered to be resistant to opioids. This hypothesis is mainly based on animal studies and single-dose opioid studies in humans but has not been confirmed in clinical practice.

      Methods

      Data were prospectively collected from 240 clinical cancer pain patients using opioids. Multiple linear regression was used for assessing the associations between the logarithm of the morphine equivalent dose (MED) at three days after admission (T = 3d) relative to admission (T = 0d) (logRMED) and type of pain (nociceptive versus mixed pain), corrected for gender, age, primary cancer site and use of non-opioid and adjuvant analgesics. As secondary outcome measures, associations between logMED and logPFent (fentanyl plasma level) at T = 3d and type of pain were assessed.

      Results

      Pain intensity between T = 0d and T = 3d was significantly and evenly reduced in patients with nociceptive pain (n = 173) and mixed pain (n = 67). Median (interquartile range) MED was 20 (10–52) and 20 (20–80) mg (T = 0d), 40 (10–67) and 40 (20–100) mg (T = 3d), median PFent (T = 3d) was 1.59 (0.58–3.19) and 1.38 (0.54–4.39) ng/ml, none of them significantly different, in patients with nociceptive and mixed pain, respectively. Neither logRMED, logMED (T = 3d), or logPFent (T = 3d) was significantly associated with type of pain, after correction for confounding factors.

      Conclusions

      We conclude that, at least in clinical cancer patients, mixed pain is as responsive to opioids as nociceptive pain.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • van den Beuken-van Everdingen M.H.
        • de Rijke J.M.
        • Kessels A.G.
        • Schouten H.C.
        • van Kleef M.
        • Patijn J.
        Prevalence of pain in patients with cancer: a systematic review of the past 40 years.
        Ann Oncol. 2007; 18: 1437-1449
        • Garcia de Paredes M.L.
        • del Moral Gonzalez F.
        • Martinez del Prado P.
        • Marti Ciriquian J.L.
        • Enrech Frances S.
        • Cobo Dols M.
        • et al.
        First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the on study.
        Ann Oncol. 2011; 22: 924-930
        • Bennett M.I.
        • Rayment C.
        • Hjermstad M.
        • Aass N.
        • Caraceni A.
        • Kaasa S.
        Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review.
        Pain. 2012; 153: 359-365
        • Jongen J.L.
        • Huijsman M.L.
        • Jessurun J.
        • Ogenio K.
        • Schipper D.
        • Verkouteren D.R.
        • et al.
        The evidence for pharmacologic treatment of neuropathic cancer pain: beneficial and adverse effects.
        J Pain Symptom Manag. 2013; 46: 581-590 e1
        • Oldenmenger W.H.
        • Sillevis Smitt P.A.
        • van Dooren S.
        • Stoter G.
        • van der Rijt C.C.
        A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: a critical appraisal.
        Eur J Canc. 2009; 45: 1370-1380
        • Bennett M.I.
        • Smith B.H.
        • Torrance N.
        • Lee A.J.
        Can pain can be more or less neuropathic? Comparison of symptom assessment tools with ratings of certainty by clinicians.
        Pain. 2006; 122: 289-294
        • Puke M.J.
        • Wiesenfeld-Hallin Z.
        The differential effects of morphine and the alpha 2-adrenoceptor agonists clonidine and dexmedetomidine on the prevention and treatment of experimental neuropathic pain.
        Anesth Analg. 1993; 77: 104-109
        • Luger N.M.
        • Sabino M.A.
        • Schwei M.J.
        • Mach D.B.
        • Pomonis J.D.
        • Keyser C.P.
        • et al.
        Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs. inflammatory pain.
        Pain. 2002; 99: 397-406
        • Arner S.
        • Meyerson B.A.
        Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain.
        Pain. 1988; 33: 11-23
        • Cherny N.I.
        • Thaler H.T.
        • Friedlander-Klar H.
        • Lapin J.
        • Foley K.M.
        • Houde R.
        • et al.
        Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies.
        Neurology. 1994; 44: 857-861
        • Portenoy R.K.
        • Foley K.M.
        • Inturrisi C.E.
        The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions.
        Pain. 1990; 43: 273-286
        • Dellemijn P.
        Are opioids effective in relieving neuropathic pain?.
        Pain. 1999; 80: 453-462
        • Mercadante S.
        • Gebbia V.
        • David F.
        • Aielli F.
        • Verna L.
        • Casuccio A.
        • et al.
        Tools for identifying cancer pain of predominantly neuropathic origin and opioid responsiveness in cancer patients.
        J Pain. 2009; 10: 594-600
        • Jongen J.L.
        • Overbeck A.
        • Stronks D.L.
        • van Zuylen L.
        • Booms M.
        • Huygen F.J.
        • et al.
        Effectiveness of a multidisciplinary consultation team for cancer pain and palliative care in a large university hospital in the Netherlands.
        BMJ Support Palliat Care. 2011; 1: 322-328
        • Treede R.D.
        • Jensen T.S.
        • Campbell J.N.
        • Cruccu G.
        • Dostrovsky J.O.
        • Griffin J.W.
        • et al.
        Neuropathic pain: redefinition and a grading system for clinical and research purposes.
        Neurology. 2008; 70: 1630-1635
      1. Landelijke richtlijn pijn bij kanker (1.0). Consensus Guideline. Utrecht: Integraal Kankercentrum Nederland; 2008 02-06-2008.

        • Pereira J.
        • Lawlor P.
        • Vigano A.
        • Dorgan M.
        • Bruera E.
        Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing.
        J Pain Symptom Manag. 2001; 22: 672-687
        • Sittl R.
        Transdermal buprenorphine in cancer pain and palliative care.
        Palliat Med. 2006; 20: s25-s30
        • de Bruijn P.
        • Kuip E.J.M.
        • Lam M.H.
        • Mathijssen R.H.J.
        • Koolen S.L.W.
        Bioanalytical methods for the quantification of hydromorphone, fentanyl, norfentanyl, morphine, morphine-3ss-glucuronide and morphine-6ss-glucuronide in human plasma.
        J Pharmaceut Biomed Anal. 2018; 149: 475-481
        • Matic M.
        • Jongen J.L.
        • Elens L.
        • de Wildt S.N.
        • Tibboel D.
        • Sillevis Smitt P.A.
        • et al.
        Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement.
        Pharmacogenomics. 2017; 18: 1133-1142
        • Loblaw D.
        A ppopulation-based study of malignant spinal cord compression in ontario.
        Clin Oncol. 2003; 15: 211-217
        • Patchell R.A.
        • Tibbs P.A.
        • Regine W.F.
        • Payne R.
        • Saris S.
        • Kryscio R.J.
        • et al.
        Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial.
        Lancet. 2005; 366: 643-648
        • Gomez-Iturriaga A.
        • Cacicedo J.
        • Navarro A.
        • Morillo V.
        • Willisch P.
        • Carvajal C.
        • et al.
        Incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: multicenter prospective observational study.
        BMC Palliat Care. 2015; 14: 48
        • Hadley G.
        • Derry S.
        • Moore R.A.
        • Wiffen P.J.
        Transdermal fentanyl for cancer pain.
        Cochrane Database Syst Rev. 2013; 10: CD010270
        • Haumann J.
        • Geurts J.W.
        • van Kuijk S.M.
        • Kremer B.
        • Joosten E.A.
        • van den Beuken-van Everdingen M.H.
        Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer.
        Eur J Canc. 2016; 65: 121-129
        • Bruera E.
        • Palmer J.L.
        • Bosnjak S.
        • Rico M.A.
        • Moyano J.
        • Sweeney C.
        • et al.
        Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study.
        J Clin Oncol. 2004; 22: 185-192
        • Bell R.F.
        • Eccleston C.
        • Kalso E.A.
        Ketamine as an adjuvant to opioids for cancer pain.
        Cochrane Database Syst Rev. 2012; 11: CD003351